EYEN Eyenovia Inc

Eyenovia to Present at Upcoming Healthcare Conferences

Eyenovia to Present at Upcoming Healthcare Conferences

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced they will present at the R.W. Baird Global Healthcare Conference taking place on September 13-14, 2022 at the Intercontinental New York Barclay Hotel and the Ladenburg Thalmann Healthcare Conference taking place on September 29, 2022 at the Sofitel Hotel in New York City. Presentation details are below:

R.W. Baird Global Healthcare Conference

Date:Wednesday, September 14, 2022
Time:10:50 – 11:20 AM ET
Location:Session IV, Morgan Suite, Mezzanine Level

Ladenburg Thalmann Healthcare Conference

Date:Thursday, September 29, 2022
Time:3:30-3:55 PM ET
Location:Track 1 – Trocadero
Webcast:

The Eyenovia management team will be participating in one-on-one meetings at both events. Investors interested in meeting with Eyenovia at either conference should contact their respective bank representative.

About Eyenovia, Inc.

Eyenovia, Inc. (Nasdaq: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

Eyenovia Investor Contact:

Eric Ribner

LifeSci Advisors, LLC



(646) 751-4363

Eyenovia Media Contact:

Norbert Lowe

Vice President, Commercial Operations

Eyenovia



EN
07/09/2022

Underlying

EYENEyenovia Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Provides Development Update on Optejet User Filled Device (UF...

Eyenovia Provides Development Update on Optejet User Filled Device (UFD) On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company’s novel Optejet UFD. The user-filled Optejet is designed to work with a...

April 10, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Me...

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing an...

March 20, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirem...

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low...

February 26, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Sen...

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has entered in...

February 24, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dis...

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including difficul...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch